ES2631611T3 - Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos - Google Patents
Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos Download PDFInfo
- Publication number
- ES2631611T3 ES2631611T3 ES13700841T ES13700841T ES2631611T3 ES 2631611 T3 ES2631611 T3 ES 2631611T3 ES 13700841 T ES13700841 T ES 13700841T ES 13700841 T ES13700841 T ES 13700841T ES 2631611 T3 ES2631611 T3 ES 2631611T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- cycloalkyl
- heteroaryl
- optionally substituted
- pirano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula I: **Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que, independientemente para cada caso: R1 es H, alquilo C1-C6, fluoroalquilo C1-C6, cicloalquilo C3-C8, CF3, heterocicloalquilo opcionalmente sustituido, arilo, heteroarilo, o una cadena lineal, ramificada o cíclica (C1-C8)-R9 en la que hasta dos unidades de CH2 pueden ser reemplazadas por O, CO, S, SO, SO2, N, CF2O NR8; R2 es alquilo C1-C6, alquilo C1-C6 deuterado, alcoxi C1-C6, alquilo C1-C6, fluoroalquilo, CF3, CHF2, O una cadena lineal, ramificada o cíclica (C1-C8)-R9 en la que hasta dos unidades de CH2 pueden ser reemplazadas por O, CO, S, SO, SO2, N, CF2O NR8; R3 es alquilo C1-C6 o halo; R8 es H, alquilo C1-C6, cicloalquilo C3-C8, CF3, o una cadena lineal, ramificada o cíclica (C1-C8)-R9 en la que hasta dos unidades de CH2 pueden ser reemplazadas por O, CO, S, SO, SO2, N, CF2, o NR, o 2 R8 juntos con los átomos a los que están unidos forman un anillo; R9 es H, CF3, CHF2, CH2F, CO2R, halo, OH, arilo opcionalmente sustituido, heteroarilo, cicloalquilo C3-C8, heterocicloalquilo, N(R)2, NRCOR, CON(R)2, CN, o SO2R; R es H, alquilo C1-C6, arilo opcionalmente sustituido, heteroarilo, cicloalquilo C3-C8 cicloalquilo, o heterocicloalquilo; el anillo A es un arilo opcionalmente sustituido, heteroarilo o heterocíclico; N es un número entero de 0 a 4 inclusive; y o es un número entero de 0 a 4 inclusive.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586875P | 2012-01-16 | 2012-01-16 | |
| PCT/US2013/021535 WO2013109521A1 (en) | 2012-01-16 | 2013-01-15 | Pyran-spirocyclic piperidine amides as modulators of ion channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2631611T3 true ES2631611T3 (es) | 2017-09-01 |
Family
ID=47595110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13700841T Active ES2631611T3 (es) | 2012-01-16 | 2013-01-15 | Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9403839B2 (es) |
| EP (1) | EP2804868B1 (es) |
| JP (1) | JP6215230B2 (es) |
| CN (1) | CN104136442B (es) |
| AU (1) | AU2013209958B2 (es) |
| CA (1) | CA2863343A1 (es) |
| ES (1) | ES2631611T3 (es) |
| MX (1) | MX2014008591A (es) |
| NZ (1) | NZ627259A (es) |
| WO (1) | WO2013109521A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2680401C2 (ru) | 2013-07-19 | 2019-02-21 | Вертекс Фармасьютикалз Инкорпорейтед | Сульфонамиды в качестве модуляторов натриевых каналов |
| SMT201800521T1 (it) | 2013-12-13 | 2018-11-09 | Vertex Pharma | Profarmaci di piridonammidi utili come modulatori di canali del sodio |
| WO2018213426A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| WO2019014352A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS |
| ES2933184T3 (es) * | 2017-11-01 | 2023-02-02 | Bristol Myers Squibb Co | Compuestos espirocíclicos como moduladores del receptor farnesoide X |
| CN108276307A (zh) * | 2018-01-17 | 2018-07-13 | 常熟浸大科技有限公司 | 3-氰基-4-烃氧基苯甲酸酯的合成方法 |
| JP2021512935A (ja) | 2018-02-12 | 2021-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 疼痛を処置する方法 |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019302534B2 (en) * | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| JP2021530478A (ja) | 2018-07-09 | 2021-11-11 | リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. | ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| EP4346818B1 (en) | 2021-06-04 | 2025-12-03 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| US20250213555A1 (en) | 2021-06-04 | 2025-07-03 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| EP4511115A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| KR20250005373A (ko) | 2022-04-22 | 2025-01-09 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| EP4511114A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN120603815A (zh) | 2022-12-06 | 2025-09-05 | 沃泰克斯药物股份有限公司 | 钠通道的取代四氢呋喃调节剂的合成方法 |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US121652A (en) | 1871-12-05 | Improvement in picture-frame hangers | ||
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO1997011940A1 (en) * | 1995-09-29 | 1997-04-03 | Eli Lilly And Company | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| AU2003274053A1 (en) * | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| US7576207B2 (en) * | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| RU2010123876A (ru) * | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| WO2009064747A2 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
| EP2307412A2 (en) * | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2010151815A2 (en) * | 2009-06-25 | 2010-12-29 | Abbott Laboratories | 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof |
| WO2010151597A1 (en) * | 2009-06-26 | 2010-12-29 | Schering Corporation | Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers |
| US10385070B2 (en) * | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
| EP2686325B1 (en) * | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
-
2013
- 2013-01-15 CN CN201380010104.4A patent/CN104136442B/zh not_active Expired - Fee Related
- 2013-01-15 JP JP2014552376A patent/JP6215230B2/ja active Active
- 2013-01-15 NZ NZ627259A patent/NZ627259A/en not_active IP Right Cessation
- 2013-01-15 AU AU2013209958A patent/AU2013209958B2/en not_active Expired - Fee Related
- 2013-01-15 US US14/372,353 patent/US9403839B2/en active Active
- 2013-01-15 CA CA2863343A patent/CA2863343A1/en not_active Abandoned
- 2013-01-15 EP EP13700841.3A patent/EP2804868B1/en active Active
- 2013-01-15 MX MX2014008591A patent/MX2014008591A/es unknown
- 2013-01-15 ES ES13700841T patent/ES2631611T3/es active Active
- 2013-01-15 WO PCT/US2013/021535 patent/WO2013109521A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20150005304A1 (en) | 2015-01-01 |
| NZ627259A (en) | 2016-12-23 |
| CA2863343A1 (en) | 2013-07-25 |
| EP2804868B1 (en) | 2017-04-12 |
| CN104136442B (zh) | 2016-12-21 |
| CN104136442A (zh) | 2014-11-05 |
| JP2015505321A (ja) | 2015-02-19 |
| JP6215230B2 (ja) | 2017-10-18 |
| AU2013209958A1 (en) | 2014-08-07 |
| HK1203074A1 (zh) | 2015-10-16 |
| EP2804868A1 (en) | 2014-11-26 |
| US9403839B2 (en) | 2016-08-02 |
| MX2014008591A (es) | 2014-08-22 |
| AU2013209958B2 (en) | 2017-09-07 |
| WO2013109521A1 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2631611T3 (es) | Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos | |
| AR085893A1 (es) | Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| CO2018012171A2 (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| MX360495B (es) | Derivados deuterados de ruxolitinib. | |
| EA201491079A1 (ru) | Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2 | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| EA201401292A2 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| ES2620379T3 (es) | Quinolina y quinoxalina amidas como moduladores de canales de sodio | |
| PE20140011A1 (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| ECSP13013074A (es) | Nuevos derivados de piridina | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| EP2677869A4 (en) | NEW CYCLIC AZABENIC ZIMIDAZOLE DERIVATIVES AS ANTIDIABETICS | |
| PE20142452A1 (es) | AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2 | |
| CR20140294A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| PE20160285A1 (es) | Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos. |